Moreover, downregulation of UBE2S enhances the effect of sorafenib, which provides a novel marker for sorafenib‐resistant HCC patients, and cotargeting of UBE2S may promote the efficacy of sorafenib. Here, UBE2S is linked to hepatocellular carcinoma.